Alkermes (ALKS) Net Cash Flow Growth (3y) (2013 - 2026)
Alkermes (ALKS) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -22.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.55% |
| Mar 31, 2026 | -205.66% |
| Dec 31, 2025 | 160.37% |
| Sep 30, 2025 | 117.08% |
| Jun 30, 2025 | 85.17% |
| Mar 31, 2025 | 58.42% |
| Dec 31, 2024 | -80.49% |
| Sep 30, 2024 | -67.09% |
| Jun 30, 2024 | 28.98% |
| Mar 31, 2024 | 18.54% |
| Dec 31, 2023 | -99.39% |
| Sep 30, 2023 | -32.93% |
| Jun 30, 2023 | 198.60% |
| Mar 31, 2023 | 44.93% |
| Dec 31, 2022 | 35.62% |
| Sep 30, 2022 | -47.80% |
| Jun 30, 2022 | 1.58% |
| Mar 31, 2022 | -9.81% |
| Dec 31, 2021 | -18.86% |
| Sep 30, 2021 | -4.70% |